JP2019512534A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512534A5 JP2019512534A5 JP2018551334A JP2018551334A JP2019512534A5 JP 2019512534 A5 JP2019512534 A5 JP 2019512534A5 JP 2018551334 A JP2018551334 A JP 2018551334A JP 2018551334 A JP2018551334 A JP 2018551334A JP 2019512534 A5 JP2019512534 A5 JP 2019512534A5
- Authority
- JP
- Japan
- Prior art keywords
- disorders
- alkyl
- compound
- pharmaceutically acceptable
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 5
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- -1 hydroxy, amino Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 208000025966 Neurological disease Diseases 0.000 claims 3
- 208000022873 Ocular disease Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 230000000926 neurological effect Effects 0.000 claims 3
- 230000003040 nociceptive effect Effects 0.000 claims 3
- 230000000771 oncological effect Effects 0.000 claims 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 3
- PBPBVEAFHHWLBB-UHFFFAOYSA-N 2,5-benzodiazonin-6-one Chemical compound C1=CC2=CC(=O)N=CC=NC=C2C=C1 PBPBVEAFHHWLBB-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16163572 | 2016-04-01 | ||
| EP16163572.7 | 2016-04-01 | ||
| PCT/EP2017/057769 WO2017167996A1 (en) | 2016-04-01 | 2017-03-31 | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512534A JP2019512534A (ja) | 2019-05-16 |
| JP2019512534A5 true JP2019512534A5 (enExample) | 2020-04-30 |
| JP6968091B2 JP6968091B2 (ja) | 2021-11-17 |
Family
ID=55650322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551334A Active JP6968091B2 (ja) | 2016-04-01 | 2017-03-31 | Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10793578B2 (enExample) |
| EP (1) | EP3436458B1 (enExample) |
| JP (1) | JP6968091B2 (enExample) |
| CN (1) | CN109219608B (enExample) |
| BR (1) | BR112018069931A2 (enExample) |
| CA (1) | CA3018907A1 (enExample) |
| EA (1) | EA201892149A1 (enExample) |
| WO (1) | WO2017167996A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| MA47106A (fr) | 2016-12-21 | 2019-10-30 | Amgen Inc | Formulations d'anticorps anti-tnf alpha |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| CN113227097B (zh) * | 2018-10-24 | 2023-09-08 | Ucb生物制药有限责任公司 | 作为tnf活性调节剂的稠合五环咪唑衍生物 |
| WO2025038927A1 (en) | 2023-08-16 | 2025-02-20 | Raythera, Inc. | Modulators of tnf alpha activity and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2517281A1 (en) | 2003-03-10 | 2004-10-14 | Pfizer Inc. | Phosphate/sulfate ester compounds and pharmaceutical compositions for inhibiting protein interacting nima (pin1) |
| TW200615273A (en) * | 2004-11-10 | 2006-05-16 | Nicholas Piramal India Ltd | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha |
| DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
| AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
| JP5977344B2 (ja) | 2011-06-20 | 2016-08-24 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ジャイレースおよびトポイソメラーゼ阻害剤のリン酸エステル |
| ES2675583T3 (es) * | 2012-06-11 | 2018-07-11 | Ucb Biopharma Sprl | Bencimidazoles moduladores de TNF-alfa |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| BR112015000675B1 (pt) * | 2012-07-13 | 2022-07-12 | UCB Biopharma SRL | Derivados de imidazopiridina como moduladores da atividade de tnf |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321730D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| SG11201701796XA (en) | 2014-10-03 | 2017-04-27 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives |
-
2017
- 2017-03-31 CN CN201780033366.0A patent/CN109219608B/zh not_active Expired - Fee Related
- 2017-03-31 CA CA3018907A patent/CA3018907A1/en active Pending
- 2017-03-31 JP JP2018551334A patent/JP6968091B2/ja active Active
- 2017-03-31 WO PCT/EP2017/057769 patent/WO2017167996A1/en not_active Ceased
- 2017-03-31 BR BR112018069931A patent/BR112018069931A2/pt not_active Application Discontinuation
- 2017-03-31 US US16/086,311 patent/US10793578B2/en active Active
- 2017-03-31 EA EA201892149A patent/EA201892149A1/ru unknown
- 2017-03-31 EP EP17714243.7A patent/EP3436458B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512535A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2019512534A5 (enExample) | ||
| JP6629947B2 (ja) | 高インスリン血症に関連した症状の処置 | |
| JP2016525135A5 (enExample) | ||
| JP2014513139A5 (enExample) | ||
| JP2019512533A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| JP2016522835A5 (enExample) | ||
| EA202090659A1 (ru) | СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ | |
| JP2013519704A5 (enExample) | ||
| JP2017512779A5 (enExample) | ||
| JP2012532112A5 (enExample) | ||
| JP2010523522A5 (enExample) | ||
| JP2015143283A5 (enExample) | ||
| JP2014513140A5 (enExample) | ||
| JP2015514808A5 (enExample) | ||
| JP2016523270A5 (enExample) | ||
| JP2009532452A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| JP2016520118A5 (enExample) | ||
| JP2016507581A5 (enExample) | ||
| JP2017517538A5 (enExample) | ||
| JP2008517913A5 (enExample) | ||
| JP2012513416A5 (enExample) |